CAR-T Therapy Process and Timeline in China: A Step-by-Step Guide for International Patients
What the full CAR-T treatment journey involves — from remote eligibility review to post-discharge follow-up — and what international patients and caregivers should prepare at each stage
Quick Answer
The full CAR-T process in China takes approximately 10–14 weeks for international patients — from initial records submission to post-infusion discharge. The process involves multiple distinct phases: remote eligibility review, leukapheresis (T-cell collection), CAR-T manufacturing (4–6 weeks, often manageable at home), conditioning chemotherapy, CAR-T infusion, and close inpatient monitoring. A structured remote review before committing to the process helps families understand what each phase involves and whether CAR-T is the right next step.
CAR-T therapy is often described in headlines as a “single infusion” that transforms relapsed cancer. The reality is more complex — and understanding the full process is essential for families planning cross-border treatment in China. CAR-T is a multi-phase, resource-intensive treatment that requires significant logistical preparation, a sustained period in China, caregiver support, and post-treatment follow-up planning.
This page is part of ChinaMed Waypoint's CAR-T & Cell Therapy specialty hub. For information on eligibility and indications, see our guide on CAR-T for lymphoma and leukemia in China.
The Full CAR-T Process: Phase by Phase
Remote Eligibility Review
Typical duration: 1–2 weeks | Location: Remote (no travel required)
International patients begin by submitting medical records for remote review by Chinese CAR-T specialists. This assessment determines whether the patient is likely to be eligible for CAR-T at a Chinese centre — and which centre and product are most appropriate.
Records typically needed:
In-Person Assessment and Leukapheresis
Typical duration: 1–2 weeks | Location: China (first trip)
Patients travel to China for the first in-person visit. The treating team conducts a comprehensive baseline assessment, then proceeds to leukapheresis — the collection of T-cells from the patient's blood using an apheresis machine. Leukapheresis typically takes 3–5 hours and is generally well-tolerated. After collection, T-cells are transported to the manufacturing facility.
After leukapheresis: Many patients can return home during the manufacturing wait (4–6 weeks) if disease is stable and travel is safe. The clinical team will advise whether bridging therapy is needed.
CAR-T Manufacturing
Typical duration: 4–6 weeks | Location: Patient may be at home
T-cells are genetically modified in a GMP-certified manufacturing facility to express the chimeric antigen receptor (CAR). Quality control testing is performed before the product is released for clinical use. Manufacturing timelines vary between products and centres. During this period, the clinical team monitors the patient's disease status, and bridging chemotherapy may be given to control disease progression while awaiting the manufactured product.
Lymphodepleting Conditioning Chemotherapy
Typical duration: approximately 5–7 days | Location: China (second trip)
Patients return to China approximately 1 week before the planned CAR-T infusion. A short course of chemotherapy (typically fludarabine and cyclophosphamide) is given to deplete the patient's existing immune cells, creating space for the CAR-T cells to expand after infusion. Conditioning causes temporary immune suppression and may cause fatigue, nausea, and infection risk.
CAR-T Infusion
Duration: 30–60 minutes (the infusion itself) | Location: China, inpatient
The manufactured CAR-T cells are infused through an intravenous line. The infusion itself is brief — typically 30–60 minutes. The days and weeks following infusion are the most intensive monitoring period. CAR-T cells begin multiplying in the body and attacking cancer cells. This expansion phase also triggers immune activation that can cause cytokine release syndrome (CRS).
Inpatient Monitoring for CRS and ICANS
Typical duration: 2–4 weeks inpatient | Location: China
The most intensive monitoring period follows infusion. The two main complications are:
Cytokine Release Syndrome (CRS)
Fever, fatigue, low blood pressure, difficulty breathing. Most cases are mild to moderate and managed with tocilizumab. Typically occurs within the first 1–7 days after infusion.
ICANS (Neurotoxicity)
Confusion, difficulty speaking, tremors, headache. Managed with corticosteroids. Chinese centres have protocols for neurological monitoring and grading.
Response Assessment and Discharge Planning
Timing: approximately 4 weeks post-infusion | Location: China (outpatient) → home
After the monitoring period, response is assessed through blood tests, imaging (PET-CT or CT), and bone marrow assessment where relevant. Patients achieving remission then transition to outpatient follow-up before discharge. International patients should receive an English-language discharge summary, a structured follow-up schedule, emergency contact protocols, and a clear handover plan for their home-country physicians.
Ready to Understand Whether CAR-T in China Is Right for Your Family?
ChinaMed Waypoint coordinates the remote eligibility review, records preparation, and logistics planning for international patients considering CAR-T in China — before any travel or financial commitment is made.
Start with a Remote Eligibility ReviewCaregiver Planning for CAR-T in China
CAR-T therapy in China requires one or more caregivers to be present — especially during the infusion and monitoring phase, when patients may be too unwell to manage independently. Planning for the caregiver role is an important part of the logistics process.
CAR-T therapy is emotionally as well as physically demanding. Families who have planned realistically — including for uncertainty, delays, and potential complications — typically manage the process more effectively than those who arrive expecting a straightforward infusion and rapid return home.
Frequently Asked Questions
How long does the entire CAR-T process take in China?
The full CAR-T process in China — from initial eligibility review to discharge after infusion and monitoring — typically takes 10–14 weeks for international patients. This includes approximately 1–2 weeks for remote eligibility review and records preparation, 1–2 weeks in China for leukapheresis (T-cell collection) and pre-assessment, 4–6 weeks for CAR-T manufacturing (during which patients may return home if stable), and 3–5 weeks in China for conditioning chemotherapy, infusion, and inpatient monitoring. Post-discharge outpatient follow-up then continues for several months.
Can international patients return home during CAR-T manufacturing?
In many cases, yes. After leukapheresis (T-cell collection) is completed, the manufacturing process takes 4–6 weeks and patients do not need to remain in China during this period. Whether return home is clinically appropriate depends on the patient's disease stability, performance status, and distance from China. The treating team will advise on whether bridging therapy is needed during the manufacturing wait and whether travel is safe.
What happens if a patient's CAR-T product cannot be manufactured successfully?
Manufacturing failure can occur in a minority of cases, particularly in patients who have received very heavy prior chemotherapy and have few viable T-cells available for collection. This risk is assessed during the eligibility evaluation — T-cell quality and viability are factors in the pre-treatment assessment. If manufacturing fails, families will work with the clinical team to explore alternative options, which may include alternative CAR-T products, clinical trials, or other treatment strategies.
What are the most common side effects during CAR-T monitoring in China?
The two most significant side effects monitored after CAR-T infusion are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS typically presents within the first 1–7 days after infusion as fever, fatigue, and in severe cases, low blood pressure and difficulty breathing. ICANS may manifest as confusion, difficulty speaking, or tremors. Chinese haematology centres with active CAR-T programmes have established protocols for managing both.
What records do international patients need to prepare for CAR-T evaluation in China?
For a remote eligibility review, international patients typically need: complete pathology reports with CD19/target antigen expression data; bone marrow biopsy reports (current); prior treatment history with regimens, dates, and response; latest imaging (PET-CT or CT, within 3 months); blood tests including CBC, organ function, HIV, hepatitis B and C serology; cardiac assessment (echocardiogram or MUGA, within 6 months); and a summary of current medications and performance status.
Medical disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions should be made in consultation with a qualified haematologist, oncologist, or CAR-T specialist. Process timelines described here are typical but may vary between centres, products, and individual patient circumstances.
Related Guides
CAR-T Therapy for Lymphoma and Leukemia in China
Approved indications, eligibility criteria, and how CAR-T is used for lymphoma and leukemia at Chinese centres.
CAR-T Therapy Cost and Access in China for International Patients
What CAR-T costs in China, how it compares internationally, what is included, and how international patients access funding and coordination support.
CAR-T Side Effects: What Happens and How to Prepare
A detailed guide to cytokine release syndrome (CRS), ICANS, and other CAR-T side effects — and how they are managed at Chinese haematology centres.
Ready to Understand the CAR-T Process in China?
ChinaMed Waypoint coordinates the full CAR-T pathway for international patients — from remote records review and eligibility assessment through logistics planning, centre selection, and post-discharge follow-up coordination.